WhiteOak Capital Pharma and Heathcare Fund Direct Plan Growth

Q: How much expense ratio is charged by WhiteOak Capital Pharma and Heathcare Fund Direct Plan Growth?

The expense ratio for WhiteOak Capital Pharma and Heathcare Fund Direct Plan Growth, or any other mutual fund, is the yearly fee you pay for managing your investments. As of 20 Mar 2026, the expense ratio charged by WhiteOak Capital Pharma and Heathcare Fund Direct Plan Growth is typically around undefined %. This fee covers fund management, administrative, and other operational costs. It is relatively low compared to actively managed funds, reflecting its direct growth option.

Q: What is the AUM of WhiteOak Capital Pharma and Heathcare Fund Direct Plan Growth?

As of 20 Mar 2026, the Assets Under Management (AUM) of WhiteOak Capital Pharma and Heathcare Fund Direct Plan Growth is approximately ₹533.0452 crore. The AUM can fluctuate based on market conditions and investor activity. It indicates the total value of assets managed by the fund.

Q: What is the NAV of WhiteOak Capital Pharma and Heathcare Fund Direct Plan Growth?

The Net Asset Value (NAV) of WhiteOak Capital Pharma and Heathcare Fund Direct Plan Growth is updated daily and reflects the per-unit value of the fund's assets. As of 20 Mar 2026 , the NAV is around undefined per unit, but this value might change based on market performance and fund holdings.

Q: What is the PE and PB ratio of WhiteOak Capital Pharma and Heathcare Fund Direct Plan Growth?

The PE ratio for WhiteOak Capital Pharma and Heathcare Fund Direct Plan Growth is 48.28 and the PB ratio is 8.05. The PE ratio is calculated by dividing the market price by the earnings per share, whereas the PB ratio is calculated by dividing the stock price by the book value per share.

Q: What is the exit load of WhiteOak Capital Pharma and Heathcare Fund Direct Plan Growth?

The exit load for WhiteOak Capital Pharma and Heathcare Fund Direct Plan Growth is undefined% if units are redeemed within 30 days from the date of investment. After this period, no exit load is applicable. This fee is charged to discourage short-term trading and ensure long-term investment.

Equity

NAV

₹ 14.13

CAGR (3 Years)

AUM (Cr)

₹ 533.05

Risk

Very High Risk

About WhiteOak Capital Pharma and Heathcare Fund Direct Plan Growth

The primary objective of the Scheme is to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. However, there can be no assurance that the investment objective of the Scheme will be realized.